INCY241220C75000
- 0.01
- 0.000.00%
Incyte Newsroom
Truist Financial Maintains Incyte(INCY.US) With Hold Rating, Maintains Target Price $74
Truist Financial Maintains Incyte(INCY.US) With Hold Rating, Announces Target Price $74
Incyte (INCY) Receives a Hold From Truist Financial
RBC Capital Maintains Incyte(INCY.US) With Hold Rating, Raises Target Price to $75
RBC Lifts Price Target on Incyte to $75 From $74, Keeps Sector Perform Rating
Wells Fargo Maintains Incyte(INCY.US) With Hold Rating, Raises Target Price to $70
Wells Fargo Adjusts Incyte's Price Target to $70 From $68, Keeps Equalweight Rating
Analysts Offer Insights on Healthcare Companies: Century Therapeutics (IPSC), Incyte (INCY) and Bicycle Therapeutics (BCYC)
Incyte Analyst Ratings
UBS Initiates Incyte(INCY.US) With Hold Rating, Announces Target Price $77
JMP Securities Maintains Incyte(INCY.US) With Hold Rating
Incyte's Mixed Clinical Results and Financial Challenges Lead to Hold Rating
Oppenheimer Maintains Incyte(INCY.US) With Buy Rating, Maintains Target Price $82
Stifel Maintains Incyte(INCY.US) With Hold Rating, Maintains Target Price $75
TD Cowen Maintains Incyte(INCY.US) With Buy Rating, Maintains Target Price $86
BMO Capital Maintains Incyte(INCY.US) With Sell Rating, Maintains Target Price $52
TD Cowen Reaffirms Their Buy Rating on Incyte (INCY)
Stifel Maintains Incyte(INCY.US) With Hold Rating, Maintains Target Price $75
Stifel Nicolaus Sticks to Their Hold Rating for Incyte (INCY)
Analysts Offer Insights on Healthcare Companies: Keros Therapeutics (KROS), Incyte (INCY) and Prenetics Group (PRE)